OsmoPrep

OsmoPrep is a brand name of sodium biphosphate/sodium phosphate, approved by the FDA in the following formulation(s):

OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate - tablet; oral)

• 
  Manufacturer: SALIX PHARMS
  
  Approval date: March 16, 2006
  
  Strength(s): 0.398GM;1.102GM ^[RLD][AB]

Has a generic version of OsmoPrep been approved?

A generic version of OsmoPrep has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to OsmoPrep and have been approved by the FDA:

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate tablet; oral)

• 
  Manufacturer: NOVEL LABS INC
  
  Approval date: December 30, 2011
  
  Strength(s): 0.398GM;1.102GM ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OsmoPrep. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Non-aqueous colonic purgative formulations
  Patent 5,616,346
  Issued: April 1, 1997
  Inventor(s): Aronchick; Craig A.
  Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of monobasic, dibasic and tribasic sodium phosphates administered in tablet or capsule form in concentrations of from 0.01 to 0.85 grams per kilogram body weight. Preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.
  
  Patent expiration dates:
  
  
  • May 18, 2013
    
    ✓ 
    Patent use: FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
    ✓ 
    Drug product
  
  



• 
  Colonic purgative composition with soluble binding agent
  Patent 7,687,075
  Issued: March 30, 2010
  Inventor(s): Skiendzielewski; Stephen & Rose; Martin & Do; Ngoc
  Assignee(s): Salix Pharmaceuticals, Ltd.
  This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.
  
  Patent expiration dates:
  
  
  • June 22, 2028
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• OsmoPrep Consumer Information (Drugs.com)
• OsmoPrep Consumer Information (Wolters Kluwer)
• OsmoPrep Consumer Information (Cerner Multum)
• Fleet Enema Consumer Information (Wolters Kluwer)
• Sodium Phosphates Consumer Information (Wolters Kluwer)
• Sodium Phosphates Enema Consumer Information (Wolters Kluwer)
• Sodium Phosphates Solution Consumer Information (Wolters Kluwer)
• Sodium biphosphate and sodium phosphate Consumer Information (Cerner Multum)